PE/Cy7 Anti-human CD16 Antibody *3G8*
The 3G8 monoclonal antibody recognizes human CD16a, a 50 - 65 kD transmembrane protein typically found on the surface of macrophages, natural killer cells, dendritic cells, monocytes and neutrophils. CD16 is a member of key cellular pathways, namely, the Fc-gamma receptor signaling pathway involved in phagocytosis. From a research standpoint, it is of biological interest due to its association with important macromolecules/ligands like IgG Fc. CD16 is a very popular antibody target, with over 25000 publications in the last decade. CD16a is frequently used in flow cytometry applications as a phenotypic marker for differentiation of cell types, particularly in the study of immunology. This antibody was purified through affinity chromatography and conjugated to PE/Cy7 (ex/em = 566/778 nm). It is compatible with the 561 nm laser and 780/60 nm bandpass filter (for example, as in the BD FACSCelesta™).
Spectrum
Open in Advanced Spectrum Viewer
Conjugation
We provide custom conjugation services for this antibody (eg. labeling of cd16a antibody with HRP). A list of available labels can be found in the table below:
For additional information about custom conjugations, please consult our services page here.
AF | AF350, AF488, AF555, AF594, AF647, AF680, AF700, AF750 |
Proteins | HRP, Alkaline Phosphatase, Streptavidin |
Tandems | APC, APC/Cy7, APC/AF750, APC/iFluor™ 700, APC/iFluor™ 750, PE, PE/Cy5, PE/Cy7, PE/AF610, PE/AF700, PE/iFluor™ 594, PE/iFluor™ 647, PE/iFluor™ 700, PE/iFluor™ 750, PE/Texas Red®, PerCP, PerCP/Cy5.5 |
Small Molecules | Biotin |
Traditional Dyes | FITC (fluorescein), TRITC, PacBlue, PacOrange, Cy3, Cy5 |
iFluor | 350, 405, 430, 450, 488, 514, 532, 546, 555, 560, 568, 594, 610, 633, 647, 660, 670, 680, 700, 710, 750, 790, 800, 810, 820, 840, 860, A7 |
mFluor | UV375, UV460, Violet 450, Violet 500, Violet 510, Violet 540, Blue 570, Green 620, Red 700, Red 780 |
For additional information about custom conjugations, please consult our services page here.
Page updated on December 17, 2024